期刊
MOLECULAR ONCOLOGY
卷 9, 期 2, 页码 527-543出版社
WILEY
DOI: 10.1016/j.molonc.2014.10.006
关键词
Triple-negative breast cancer; Epidermal growth factor receptor; PTEN; shRNA screen
类别
资金
- National Cancer Institute [CA16672]
- Cell Evaluation & Therapy Shared Resource [P30 CA138313]
- Genomics Shared Resource Facilities, Hollings Cancer Center, Medical University of South Carolina
- National Institutes of Health National Cancer Institute [R01CA130933]
A subset of triple negative breast cancer (TNBC) is characterized by overexpression of the epidermal growth factor receptor (EGER) and loss of PTEN, and patients with these determinants have a poor prognosis. We used cell line models of EGFR-positive/PTEN null TNBC to elucidate the signaling networks that drive the malignant features of these cells and cause resistance to EGER inhibitors. In these cells, amphiregulin (AREG)-mediated activation of EGFR results in up-regulation of fibronectin (FN1), which is known to be a mediator of invasive capacity via interaction with integrin beta 1. EGFR activity in this PTEN null background also results in Wnt/beta-catenin signaling and activation of NF-kappa B. In addition, AKT is constitutively phosphorylated in these cells and is resistant to gefitinib. Expression profiling demonstrated that AREG-activated EGER regulates gene expression differently than EGF-activated EGFR, and functional analysis via genome-scale shRNA screening identified a set of genes, including PLK1 and BIRC5, that are essential for survival of SUM-149 cells, but are uncoupled from EGFR signaling. Thus, our results demonstrate that in cells with constitutive EGFR activation and PTEN loss, critical survival genes are uncoupled from regulation by EGER, which likely mediates resistance to EGFR inhibitors. (C) 2014 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据